April 03, 2026

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls

Conexiant

April 02, 2026

USDA Alerts on Lead in Walmart Chicken Nuggets

Detected lead could be up to five times FDA’s interim reference level for children

Conexiant

April 01, 2026

Case Report Shows Carbimazole's ‘Triple-Hit’

Diffuse alveolar hemorrhage with coexistent antiphospholipid syndrome complicated anticoagulation therapy and created competing bleeding and thrombosis risks.

Conexiant

March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 30, 2026

A Two-Biomarker Signal for Alzheimer’s Disease

Dual plasma biomarkers may improve identification of established Alzheimer’s disease and signal faster decline

Conexiant

March 23, 2026

MRI Identifies 3 Friedreich Ataxia Subtypes

Machine learning analysis of structural MRI reveals distinct patterns of neurodegeneration that vary in their association with disease severity

Conexiant

March 18, 2026

Side Effects: The Nose Knows

A nasal swab may detect Alzheimer's before symptoms appear — and the immune system is already loud about it

Conexiant

March 17, 2026

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

Dual-drug therapy showed signals of slower disease progression and reduced complications in patients with ALS.

Conexiant

March 16, 2026

Mapping Neurodegeneration with Spatial Glycoproteomics 

Combined proteomic and glycomic profiling reveals molecular signatures of Alzheimer’s and Lewy body disease 

The Analytical Scientist

March 12, 2026

The 60 Percent Diagnostic Gap in M/E

What earlier mNGS testing could mean for labs and clinicians

The Pathologist